Preclinical study demonstrates cell-type-specific modulation of α7 nicotinic receptors in mouse brain cells, highlighting a targeted platform for treating receptor dysregulation.
Precise control of the α7 nicotinic acetylcholine receptor (α7-nAChR) in specific brain cell types is crucial for understanding its role in neural circuit function and disease. Here, we introduce a set of AAV.PHP.eB-based gene delivery vectors optimized for cell-type-specific downregulation or overexpression of α7-nAChR in the adult mouse brain. Using promoters for neuronal or astrocytic targeting, we achieved efficient cell-type modulation of α7-nAChR after intra-hippocampal administration. These vectors provide a versatile platform for investigating α7-nAChR-dependent mechanisms in vivo and advancing the preclinical development of targeted interventions for neurological disorders characterized by receptor dysregulation.
No takes yet. Share an insight, caveat, or question.
Puliatti et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: